Exagen Inc. (NASDAQ:XGN) Short Interest Update

Exagen Inc. (NASDAQ:XGN) was the recipient of a significant drop in short interest in February. As of February 28th, there was short interest totalling 23,000 shares, a drop of 29.2% from the February 13th total of 32,500 shares. Based on an average daily volume of 166,100 shares, the short-interest ratio is currently 0.1 days. Approximately 0.3% of the shares of the company are short sold.

Exagen Price Performance

Shares of NASDAQ:XGN opened at $3.62 on Tuesday. The company has a 50 day moving average of $3.78 and a 200 day moving average of $3.58. The stock has a market cap of $64.79 million, a P/E ratio of -3.85 and a beta of 1.40. Exagen has a 12 month low of $1.30 and a 12 month high of $6.22. The company has a current ratio of 4.05, a quick ratio of 4.05 and a debt-to-equity ratio of 1.54.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. William Blair reiterated an “outperform” rating on shares of Exagen in a research note on Wednesday, March 12th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $8.00 target price on shares of Exagen in a research note on Monday, January 13th. Finally, Canaccord Genuity Group lifted their target price on shares of Exagen from $5.00 to $7.00 and gave the stock a “buy” rating in a research note on Friday, January 3rd.

Hedge Funds Weigh In On Exagen

Several hedge funds have recently bought and sold shares of the company. Corient Private Wealth LLC purchased a new position in Exagen in the 4th quarter worth approximately $45,000. Virtu Financial LLC purchased a new position in Exagen in the 4th quarter worth approximately $46,000. Marshall Wace LLP purchased a new position in Exagen in the 4th quarter worth approximately $66,000. Northern Trust Corp grew its stake in Exagen by 16.7% in the 4th quarter. Northern Trust Corp now owns 18,375 shares of the company’s stock worth $75,000 after buying an additional 2,630 shares in the last quarter. Finally, Palumbo Wealth Management LLC grew its stake in Exagen by 13.5% in the 4th quarter. Palumbo Wealth Management LLC now owns 86,704 shares of the company’s stock worth $355,000 after buying an additional 10,340 shares in the last quarter. Hedge funds and other institutional investors own 75.25% of the company’s stock.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).